Patients' Self-Assessment of the Symptoms and Impact of Opioid-Induced Constipation: Results From a Prospective, Observational Cohort Study of Japanese Patients With Cancer.
Many patients who have cancer consider opioid-induced constipation (OIC) to be a burdensome side effect of opioid treatment. To evaluate patient-reported outcomes in Japanese patients with cancer pain and opioid-induced constipation. This prospective, observational study evaluated OIC incidence for 2 weeks in patients with cancer after they initiated strong opioid therapy. Rome IV criteria, physicians' diagnoses, spontaneous bowel movements (SBMs), Bowel Function Index (BFI), and patients' daily self-assessments were used. Changes from baseline in Patient Assessment of Constipation Symptoms (PAC-SYM) and Patient Assessment of Constipation Quality of Life (PAC-QOL) scores were compared between patients with and without OIC. Patients and health care providers (HCPs) completed study-specific questionnaires about OIC burden, treatment satisfaction, and patient-provider communications. Among 212 enrolled patients, the incidence of OIC was 47.6% by patients' self-assessments, with a cumulative incidence of 30.2% by Day 3 and 43.5% by Day 7. PAC-SYM and PAC-QOL overall scores from patients with OIC worsened significantly from baseline compared to patients without OIC by most diagnostic criteria, with the exception of SBM frequency for PAC-QOL. Patients and HCPs were generally satisfied with OIC treatment; however, 53.6% of patients and ∼40.0% of HCPs reported that OIC affected pain management. Most patients and HCPs reported that OIC conditions were sufficiently or essentially communicated. After starting opioid therapy, patients recognized OIC onset and its impact on cancer pain management, highlighting the need for effective patient-provider communications, diagnosis, and treatment of OIC to improve QOL for patients with cancer receiving opioid analgesics.